/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Design Automation Conference 2019 Exhibitor Profiles
LAS VEGAS–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/56DAC?src=hash” target=”_blank”gt;#56DAClt;/agt;–The 56th Design Automation Conference runs June 2 – 6, 2019
at the Las Vegas Convention Center.
Business Wire is the official
news distribution partner for DAC 2019. Exhibitor profiles from
the conference are listed below.
***
Company: | Achronix Semiconductor Corporation |
Booth: | 861 |
Web: | https://www.achronix.com |
Achronix Semiconductor Corporation is a privately held, fabless semiconductor corporation based in Santa Clara, California and offers high-performance FPGA and embedded FPGA (eFPGA) solutions. Achronix’s history is one of pushing the boundaries in the high-performance FPGA market. Achronix offerings include programmable FPGA fabrics, discrete high-performance and high-density FPGAs with hardwired system-level blocks, datacenter and HPC hardware accelerator boards, and best-in-class EDA software supporting all Achronix products. |
|
Company: | AMIQ EDA srl. |
Booth: | 854 |
Web: | www.dvteclipse.com |
AMIQ EDA provides tools – DVT Eclipse IDE, DVT Debugger Add-On, Verissimo Linter, and Specador Documentation Generator – that enable design and verification engineers increase the speed and quality of new code development, simplify legacy code maintenance, accelerate language and methodology learning, and improve source code reliability. Working with 100+ companies in 30+ countries, AMIQ EDA is recognized for its high quality products and customer service responsiveness. |
|
Company: | AnaGlobe Technology, Inc. |
Booth: | 934 |
Web: | http://www.anaglobe.com |
AnaGlobe is a Taiwanese EDA company, has 2 major layout platforms, THUNDER & GOLF. THUNDER is a versatile layout integration platform to support heavy layout handling efforts from post P&R, IP merge automation & management, physical ECO verification (LVL, connectivity, etc.), DRC/LVS debugging interface, and even (in-line inspection) defect-to-layout mapping, failure analysis and chip-package integration (fanout, interposer and substrate routing, pins connectivity, etc.). |
|
GOLF is a custom layout platform with a simple yet GUI-mode powerful PCell Designer for diversified applications. PCells are easily created, previewed and debugged by PCell Designer. |
|
AnaGlobe differentiates product to satisfy specific and individual user requests. |
|
Company: | Breker Verification Systems |
Booth: | 611 |
Web: | https://brekersystems.com/ |
Breker Verification Systems will demonstrate at DAC its portfolio of Portable Stimulus solutions, a standard means to specify verification intent and behaviors reusable across target platforms. Demos will highlight how a graph-based verification and the synthesis approach enables development of powerful test sets from abstract scenario models. Its Trek Portable Stimulus Portfolio is Graph-based to make complex scenarios comprehensible, Portable, eliminating test redundancy across the verification process, and Shareable to foster team communication and reuse. Intelligent Testbench tools and apps allows synthesis of high-coverage, powerful test cases for deployment into a variety of UVM to SoC verification environments. |
|
DAC attendees can schedule demonstrations at https://brekersystems.com/dac/. |
|
Company: | Cadence Design Systems, Inc. |
Booth: | 915 |
Ticker Symbol & Exchange: | NASDAQ: CDNS |
Web: | www.cadence.com |
Cadence enables electronic systems and semiconductor companies to create the innovative end products that are transforming the way people live, work and play. Cadence software, hardware and semiconductor IP are used by customers to deliver products to market faster. The company’s System Design Enablement strategy helps customers develop differentiated products—from chips to boards to systems—in mobile, consumer, cloud datacenter, automotive, aerospace, IoT, industrial and other market segments. Cadence is listed as one of Fortune Magazine’s 100 Best Companies to Work For. Learn more at cadence.com. |
|
Company: | Coventor, A Lam Research Company |
Booth: | 835 |
Web: | www.coventor.com |
Coventor® is the market leader in automated solutions for developing semiconductor process technology, as well as micro-electromechanical systems (MEMS). Coventor serves a worldwide customer base of integrated device manufacturers, memory suppliers, fabless design houses, independent foundries, and R&D organizations. Its SEMulator3D modeling and analysis platform is used for fast and accurate ‘virtual fabrication’ of advanced manufacturing processes, allowing engineers to understand manufacturing effects early in the development process and reduce time-consuming and costly silicon learning cycles. Its CoventorMP MEMS design platform is used to develop MEMS-based products for automotive, aerospace, industrial, defense, and consumer electronics applications. The company is headquartered in Cary, North Carolina, with development and sales offices worldwide. |
|
Company: | Defacto Technologies |
Booth: | 667 |
Web: | www.defactotech.com |
After a first success on moving traditional DFT checks to RTL, Defacto shifted its focus, 10 years ago, on providing SoC design solutions to help reaching aggressive PPA requirements cost-effectively. Defacto has proven the effectiveness of STAR as a design platform for large SoCs. |
|
By adopting Defacto’s STAR design solutions, major semiconductor companies are continuously moving from traditional and painful SoC design tasks to the Defacto’s joint “Build & Signoff” design methodology. The related ROI has been proven for hundreds of projects. |
|
Company: | Design And Reuse |
Booth: | 329 |
Web: |
https://www.design-reuse.com, http://www.design-reuse-embedded.com, www.design-reuse.cn |
Founded in 1997, D&R became the worldwide leader as a B2B portal in the IP/SoC field with its community of 42,000 registered users, 75,000 Absolute Unique Visitors/Month, 18,000 daily updated IP/SOC products, and news broadcast to 27,000 subscribers. |
|
Based on more than 20 years experience, D&R sells IPMSTM: a Java/XML multi-application, configurable platform, offering a comprehensive solution for IP management including smart IP delivery and smart computerized contract support, as well as an unique intelligent software tool license management solution providing user behavior profiling, and cost sharing, leading to well informed business decision making. |
|
Company: | EDDR Software |
Booth: | 633 |
Web: | www.eddrs.com |
EDDR Software is a company that works with customers and partners in order to help ENGINEER, DESIGN, DEVELOP, and RESEARCH solutions for barriers created by technology and software in their business. EDDRS also helps bridge gaps that may arise with changing technologies and requirements. EDDRS has tools to help clients produce products for their customers more efficiently and with higher performance. Check out some of them at https://www.eddrs.com/pg/products. |
|
Company: | Faraday Technology Corporation |
Booth: | 1012 |
Ticker Symbol & Exchange: | TWSE: 3035 |
Web: | https://www.faraday-tech.com |
Faraday Technology Corporation (TWSE: 3035) is a leading fabless ASIC and silicon IP provider. From specification level to GDSII-in, our flexible business engagement model allows customers to check-in at various design phases in maximizing ASIC implementation efficiency. |
|
Faraday’s comprehensive IP portfolio and best-in-class IP customization service have enabled customers’ products to address various applications and market segments effortlessly. |
|
Since 1993, Faraday has been cooperating with top-tier suppliers of IP, EDA, manufacturing, packaging, and testing, completing more than 2,200 tapeouts resulting in hundreds of millions chips shipped worldwide a year. |
|
Company: | Menta |
Booth: | 626 |
Web: | www.menta-efpga.com |
For ASIC and SoCs designers who need fast, right-the-first time design and fast time to volume, Menta is the proven eFPGA pioneer whose design-adaptive standard cells based architecture and state-of-the-art tool set provides the highest degree of design customization, best-in-class testability and fastest time-to-volume for SoC design targeting any production node at any foundry. |
|
Company: | OneSpin Solutions |
Booth: | 308 |
Web: | www.onespin.com |
OneSpin will feature at DAC its full complement of certified IC integrity verification solutions for building functionally correct, safe, secure and trusted integrated circuits. Solutions are based on OneSpin’s widely used formal verification technology and assure the integrity of SoCs, ASICs and FPGAs. Partners include leaders worldwide in automotive and industrial applications; defense; avionics; artificial intelligence and machine learning; consumer electronics; and communications. Its advanced solutions are well-suited for developing heterogeneous computing platforms, using programmable logic, and designing and integrating processor cores, such as RISC-V. OneSpin’s customer-oriented commitment is fundamental to its growth and success. |
|
Connect with OneSpin at: | |
Twitter: https://twitter.com/OneSpinSolution | |
LinkedIn: https://www.linkedin.com/company/onespin-solutions | |
Facebook: https://www.facebook.com/OneSpinSolutions | |
Company: | OpenText |
Booth: | 1117 |
Ticker Symbol & Exchange: | OTEX NASDAQ |
Web: | https://www.opentext.com/ |
OpenText Connectivity products, formerly Hummingbird provides web-based remote access and virtual desktop infrastructure (VDI) software for UNIX, Linux and Windows applications. |
|
OpenText Exceed TurboX (ETX) is designed from the ground up to enable session resilience and local-like responsiveness for graphically demanding applications, even over high latency WAN connections. |
|
Many leading semiconductor companies are successfully using ETX to achieve blazing fast access from anywhere to chip layout applications and other EDA tools. |
|
Company: | PRO DESIGN Electronic GmbH |
Booth: | 635 |
Web: | https://www.profpga.com/ |
PRO DESIGN is a leading provider of FPGA-based Prototyping systems. PRO DESIGN’s product family proFPGA is a very flexible high-performance FPGA system which is mainly used for ASIC Prototyping and pre-silicon software development. The modular concept of the proFPGA system, consisting of different motherboards, FPGA modules, daughter boards and interconnects allows the user to adjust it for almost any type of application. PRO DESIGN is offering FPGAs produced by XILINX and Intel, those can be Mix and Matched on one proFPGA System. |
|
Company: | SANKALP SEMICONDUCTOR |
Booth: | 510 |
Web: | www.sankalpsemi.com |
Sankalp Semiconductor offers an integrated portfolio of services and solutions to its customers in key semiconductor domains including analog & mixed signal, digital, high-speed physical interface IP, Embedded Memory Compiler, IOs & EDA modeling. Sankalp is a preferred semiconductor design service partners to multiple Fortune 500 companies in the Automotive, Consumer, Networking, Wireless, IoT, Medical electronics & Foundry space. The company enables its customers deliver first time right silicon & engage with product engineering teams across the globe to design SoCs. Sankalp is based in Palo Alto, California & Hubli, India with offices in USA, India, Canada, Germany, Malaysia and Japan. |
|
Company: | Sigasi |
Booth: | 646 |
Web: | www.sigasi.com |
Sigasi radically redefines digital design. Our design entry tool Sigasi Studio drastically improves hardware designer productivity by helping to write, inspect and modify digital circuit designs in the most intuitive way. Advanced features such as intelligent autocompletes and code refactoring, make VHDL, Verilog and SystemVerilog design easier, more efficient. |
|
Sigasi, has formed partnerships with FPGA and EDA companies including Altera, Xilinx and Aldec. The Sigasi Studio XL platform is used worldwide by industry leaders in the fields of healthcare, consumer electronics, industrial automation, telecom, aerospace and defense. |
|
Company: | Silicon Creations |
Booth: | 525 |
Web: | www.siliconcr.com |
Silicon Creations is focused on providing world-class silicon intellectual property (IP) for precision and general-purpose timing (PLLs), SerDes and high-speed differential I/Os. Silicon Creations’ IP is in production from 7 to 180-nanometer process technologies. With a complete commitment to customer success, its IP has an excellent record of first silicon to mass production in customer designs. Silicon Creations, founded in 2006, is self-funded and growing. The company has development centers in Atlanta, Ga., and Krakow, Poland, and worldwide sales representation. For more information, visit www.siliconcr.com. |
|
Company: | SmartDV Technologies |
Booth: | 514 |
Web: | www.Smart-DV.com |
SmartDV Technologies, the Proven and Trusted choice for Verification Intellectual Property (VIP), will be in DAC Booth #514 with demonstrations of Smart ViPDebug, its new protocol debugger that reduces debug time by rapidly identifying violations. Also highlighted will be SmartDV’s Compute Express Link (CXL) and Ethernet Time-Sensitive Networking (TSN) VIP solutions, along with its extensive VIP portfolio used in hundreds of networking, storage, automotive, bus, MIPI and display chip projects. SmartDV’s VIP is compatible with all verification languages, platforms and methodologies supporting all simulation, emulation and formal verification tools used in a coverage-driven chip design verification flow. |
|
DAC attendees can schedule demonstrations through SmartDV’s online scheduler: http://smart-dv.com/dac.html. |
|
Company: | Univa |
Booth: | 1233 |
Web: | www.univa.com |
Univa is the leading innovator of workload management solutions that optimize throughput and performance of applications, containers, and services. Univa manages workloads automatically by maximizing shared resources and enabling enterprises to scale compute resources across on-premise, hybrid and cloud infrastructures. Univa’s solutions help hundreds of companies to manage thousands of applications and run billions of tasks every day to obtain actionable insights and achieve faster time-to-results. Univa is headquartered in Chicago, with offices in Canada and Germany. |
|
Company: | Verific Design Automation |
Booth: | 638 |
Web: | www.verific.com |
At DAC, Verific will celebrate 20 years as the leading provider of SystemVerilog, Verilog, VHDL and UPF Parser Platforms, used by EDA, FPGA and semiconductor companies worldwide. Verific’s R&D and applications staff will explain how its SystemVerilog, VHDL and UPF parsers, as well as its “Verific with INVIO” platform enable project groups to develop advanced EDA products quickly and cost effectively. Demos of the INVIO platform will illustrate the ways in which its SystemVerilog- and VHDL-language agnostic Python and C++ APIs simplify and streamline a Verific user’s design environment to accelerate tool development. |
|
Engage with Verific at: | |
Email: [email protected] | |
LinkedIn: https://www.linkedin.com/company-beta/810695 |
***
Qualified members of the press please note the following important
information.
Exhibitor News:
http://www.tradeshownews.com/events/design-automation-conference-2019/
Press Information:
https://dac.com/content/press-registration
About Business Wire
Business Wire, a Berkshire
Hathaway company, is the global leader in news
release distribution and regulatory
disclosure. Investor relations, public relations, public policy and
marketing professionals rely on Business Wire for secure and accurate
distribution of market-moving news and multimedia. Founded in 1961,
Business Wire is a trusted source for news organizations, journalists,
investment professionals, and regulatory authorities, delivering news
directly into editorial systems and leading online news sources via its
multi-patented NX Network. Business Wire has 18 newsrooms worldwide to
meet the needs of communications professionals and news media.
Learn more at www.businesswire.com.
Follow us on Twitter @businesswire.
Contacts
Jim Liebenau
+1.310.820.9473
Twitter: @tradeshownews
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Innocan
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use
HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].
Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.
Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.“
Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:
“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”
About Innocan
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary note regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market
[2] https://www.cdc.gov/opioids/data/index.html
Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html
Curaleaf
Curaleaf Completes Acquisition of Northern Green Canada
Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom
NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.
Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.
“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”
The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.
Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.
INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]
MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html
-
Cannabis2 weeks ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis2 weeks ago
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis2 weeks ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services
-
transfer1 week ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Cannabis6 days ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Cannabis6 days ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
CCELL®1 week ago
CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer